JP2019524889A - 骨疾患の治療のためのＰＰＡＲγアゴニスト - Google Patents

骨疾患の治療のためのＰＰＡＲγアゴニスト Download PDF

Info

Publication number
JP2019524889A
JP2019524889A JP2019530368A JP2019530368A JP2019524889A JP 2019524889 A JP2019524889 A JP 2019524889A JP 2019530368 A JP2019530368 A JP 2019530368A JP 2019530368 A JP2019530368 A JP 2019530368A JP 2019524889 A JP2019524889 A JP 2019524889A
Authority
JP
Japan
Prior art keywords
subject
int131
effective amount
therapeutically effective
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019530368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524889A5 (cg-RX-API-DMAC7.html
Inventor
デニス ランフェアー
デニス ランフェアー
Original Assignee
インテクリン セラピューティクス インコーポレイテッド
インテクリン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インテクリン セラピューティクス インコーポレイテッド, インテクリン セラピューティクス インコーポレイテッド filed Critical インテクリン セラピューティクス インコーポレイテッド
Publication of JP2019524889A publication Critical patent/JP2019524889A/ja
Publication of JP2019524889A5 publication Critical patent/JP2019524889A5/ja
Priority to JP2022090843A priority Critical patent/JP2022116294A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
JP2019530368A 2016-08-18 2017-08-18 骨疾患の治療のためのＰＰＡＲγアゴニスト Pending JP2019524889A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022090843A JP2022116294A (ja) 2016-08-18 2022-06-03 骨疾患の治療のためのＰＰＡＲγアゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376732P 2016-08-18 2016-08-18
US62/376,732 2016-08-18
PCT/US2017/047584 WO2018035449A1 (en) 2016-08-18 2017-08-18 Pparϒ agonist for treatment of bone disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022090843A Division JP2022116294A (ja) 2016-08-18 2022-06-03 骨疾患の治療のためのＰＰＡＲγアゴニスト

Publications (2)

Publication Number Publication Date
JP2019524889A true JP2019524889A (ja) 2019-09-05
JP2019524889A5 JP2019524889A5 (cg-RX-API-DMAC7.html) 2020-10-01

Family

ID=61197122

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019530368A Pending JP2019524889A (ja) 2016-08-18 2017-08-18 骨疾患の治療のためのＰＰＡＲγアゴニスト
JP2022090843A Withdrawn JP2022116294A (ja) 2016-08-18 2022-06-03 骨疾患の治療のためのＰＰＡＲγアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022090843A Withdrawn JP2022116294A (ja) 2016-08-18 2022-06-03 骨疾患の治療のためのＰＰＡＲγアゴニスト

Country Status (11)

Country Link
US (1) US20190167660A1 (cg-RX-API-DMAC7.html)
EP (1) EP3500269A4 (cg-RX-API-DMAC7.html)
JP (2) JP2019524889A (cg-RX-API-DMAC7.html)
KR (1) KR20190065252A (cg-RX-API-DMAC7.html)
CN (1) CN109843292A (cg-RX-API-DMAC7.html)
AU (1) AU2017313842A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019003133A2 (cg-RX-API-DMAC7.html)
CA (1) CA3033971A1 (cg-RX-API-DMAC7.html)
EA (1) EA201990513A1 (cg-RX-API-DMAC7.html)
SG (2) SG10202101500WA (cg-RX-API-DMAC7.html)
WO (1) WO2018035449A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220070057A (ko) 2015-03-09 2022-05-27 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
SG11201909046XA (en) 2017-04-03 2019-10-30 Coherus Biosciences Inc PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007507537A (ja) * 2003-10-03 2007-03-29 アムジェン インコーポレーテッド 強力な抗糖尿病薬化合物の塩および多形体
JP2007527918A (ja) * 2004-03-08 2007-10-04 アムジェン インコーポレイテッド Ｐｐａｒガンマ活性の治療的調節
WO2016054728A1 (en) * 2014-10-10 2016-04-14 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407587A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited Ppar.gamma. modulators
AU2014212740B2 (en) * 2013-01-30 2015-12-24 Intekrin Therapeutics, Inc. PPARy agonists for treatment of multiple sclerosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007507537A (ja) * 2003-10-03 2007-03-29 アムジェン インコーポレーテッド 強力な抗糖尿病薬化合物の塩および多形体
JP2007527918A (ja) * 2004-03-08 2007-10-04 アムジェン インコーポレイテッド Ｐｐａｒガンマ活性の治療的調節
WO2016054728A1 (en) * 2014-10-10 2016-04-14 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AM J PHYSIOL ENDOCRINOL METAB, vol. 302, JPN6021020560, 2012, pages 552 - 560, ISSN: 0004699790 *
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 331, JPN6021020566, 2005, pages 520 - 526, ISSN: 0004699794 *
BLOOD, vol. 118(22), JPN6021020567, 2011, pages 5872 - 5882, ISSN: 0004699795 *
DIABETES CARE, vol. 37, JPN6021020563, 2014, pages 1918 - 1923, ISSN: 0004699792 *
DISEASE MARKERS, vol. 2014, JPN6021020572, 2014, pages 14 pages, ISSN: 0004518958 *
HTTPS://PROFESSIONAL.DIABETES.ORG/ABSTRACT/T0903131-SELECTIVE-MODULATOR-PPAR-GAMMA-ACTIVITY-INCREASE, JPN6021020564, 2004, ISSN: 0004699793 *
JOURNAL OF STEROID BIOCHEMISTRY & MOLECULAR BIOLOGY, vol. 142, JPN6021020570, 2014, pages 155 - 170, ISSN: 0004518957 *
LIFE SCIENCES, vol. 135, JPN6021020569, 2015, pages 55 - 67, ISSN: 0004518956 *
PPAR RESEARCH, vol. 2008, JPN6021020562, 2008, pages 9 pages, ISSN: 0004699791 *

Also Published As

Publication number Publication date
EP3500269A1 (en) 2019-06-26
CA3033971A1 (en) 2018-02-22
WO2018035449A1 (en) 2018-02-22
JP2022116294A (ja) 2022-08-09
SG11201901328VA (en) 2019-03-28
US20190167660A1 (en) 2019-06-06
EA201990513A1 (ru) 2019-08-30
SG10202101500WA (en) 2021-03-30
CN109843292A (zh) 2019-06-04
EP3500269A4 (en) 2020-04-15
AU2017313842A1 (en) 2019-03-07
KR20190065252A (ko) 2019-06-11
BR112019003133A2 (pt) 2019-05-21

Similar Documents

Publication Publication Date Title
Tabatabaei-Malazy et al. New horizons in treatment of osteoporosis
Girotra et al. The use of parathyroid hormone in the treatment of osteoporosis
Henriksen et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2
Ellegaard et al. Parathyroid hormone and bone healing
JP5984674B2 (ja) サイトカインアンタゴニスト及びコルチコステロイドを有する併用製剤
JP2016517883A (ja) Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
Kashii et al. Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: a case report
Xu et al. Effects of different dosages of parathyroid hormone-related protein 1–34 on the bone metabolism of the ovariectomized rat model of osteoporosis
JP2022116294A (ja) 骨疾患の治療のためのＰＰＡＲγアゴニスト
Zhao et al. Locally administrated perindopril improves healing in an ovariectomized rat tibial osteotomy model
Huang et al. Combination therapy with BMP‑2 and psoralen enhances fracture healing in ovariectomized mice
Pal et al. Oral dosing of pentoxifylline, a pan-phosphodiesterase inhibitor restores bone mass and quality in osteopenic rabbits by an osteogenic mechanism: A comparative study with human parathyroid hormone
Dubois et al. Testosterone restores body composition, bone mass, and bone strength following early puberty suppression in a mouse model mimicking the clinical strategy in trans boys
Abo-Elenin et al. An overview of osteoporosis and possible treatment approaches
RU2693484C1 (ru) Антагонисты гастрина для лечения и профилактики остеопороза
JP2008540328A (ja) 脱灰骨基質（ｄｅｍｉｎｅｒａｌｉｚｅｄｂｏｎｅｍａｔｒｉｘ）の活性化抽出
JP2020530031A (ja) 前立腺癌治療における新しいアジュバント療法
EP1385527B2 (en) Use of 2-alpha-cyano-4-alpha, 5-alpha-epoxyandrostan-17-beta-ol-3-one derivatives for lowering levels of serum cortisol and for the treatment of clinical conditions associated thereof
JP2005526022A5 (ja) 関節リウマチの処置
Vashghani Farahani et al. The effects of pentoxifylline adminstration on fracture healing in a postmenopausal osteoporotic rat model
JP2012522789A (ja) 骨粗鬆症の治療法
JP6279529B2 (ja) 虚弱を治療する方法
Yu et al. Teriparatide-induced alleviation of medication-related osteonecrosis of the jaw: Potential molecular mechanisms
Cosman Teriparatide and abaloparatide treatment for osteoporosis
Lopez-Rubalcava et al. Blockade of the anxiolytic-like action of ipsapirone and buspirone, but not that of 8-OH-DPAT, by adrenalectomy in male rats

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200819

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210319

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220207